A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Corporations, high-stakes biomedical research, and research misconduct: yes they can (and sometimes do)
2021
Journal of Law and the Biosciences
Science has long been vulnerable to research misconduct (RM). Biomedical sciences, with vast financial stakes, carry heightened temptations. However, RM is standardly seen as an undertaking of individual scientists, not as something that could be committed by an organization such as a corporation or university. Rather, organizations are generally regarded merely as supervisors to encourage scientific integrity and investigate suspected RM. Indeed, federal regulations expressly embrace this
doi:10.1093/jlb/lsab014
fatcat:z4ahphjphjfifloz6dw5zq7p5a